Apr 10, 2026 · “This approval provides a new treatment option for adults living with familial chylomicronemia syndrome, an inherited condition that can lead to inflammation of the pancreas, …

TRYNGOLZA (olezarsen) is a prescription medicine used along with diet to reduce triglycerides (fat in the blood) in the treatment of adults with a condition that keeps the body from breaking down fats …

FDA has approved Tryngolza (olezarsen), used with diet, to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Tryngolza (olezarsen) was approved in 2024 and is the first and only FDA-approved medicine to treat people with FCS along with a low-fat diet. What Is Familial Chylomicronemia Syndrome (FCS)?

TRYNGOLZA® is the first FDA-approved adjunctive therapy to diet for familial chylomicronemia syndrome (FCS) in adults. See Full Safety & PI.

Apr 15, 2025 · This review aims to evaluate the efficacy and safety of olezarsen (Tryngolza) in treating familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by severe …

Sep 19, 2025 · Tryngolza (olezarsen) is approved in the United States and the European Union for adults with familial chylomicronemia syndrome (FCS). Tryngolza is administered as an 80 mg subcutaneous …

Exciting news! The U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA (olezarsen), developed by Ionis, as the first-ever treatment for Familial Chylomicronemia Syndrome (FCS). FCS is a …

Apr 10, 2026 · MHRA has approved olezarsen (Tryngolza), an injectable antisense oligonucleotide therapy administered subcutaneously, for the treatment of familial chylomicronemia syndrome (FCS) …

Dec 20, 2024 · The FDA has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.